Pager, a virtual healthcare platform for helping patients from initial triage to follow-up care, raises $70M Series C, as a mix of equity and debt
Context & Ripple Effects
Pager's $70M round lands mid-way through a funding wave that has been building since 2020, when PatientPing raised its own $60M Series C for care coordination and Zocdoc pivoted from patient scheduling into telehealth during the pandemic. Each of those rounds funded one slice of the virtual-care journey; Pager is raising against the whole arc, from initial triage through follow-up.
The structure of the raise matters as much as the size: equity plus debt mirrors what Berlin-based Patient21 used in its €100M Series C, suggesting blended capital is becoming the default instrument for healthcare platforms scaling physical and operational footprints.
First-order effects
- Pager gains runway to compete on breadth — covering triage, treatment routing, and follow-up — against rivals like Curai's chat-based doctor support tool and 98point6's AI-triage service, which each own only part of the patient journey.
Second-order effects
- Point-solution competitors face pressure to widen scope or get absorbed: Zocdoc already moved from scheduling into telehealth, and Pager's full-journey positioning makes standalone triage or follow-up tools look like acquisition targets.
Third-order effects
- If blended equity-debt rounds keep appearing in this space — Pager and Patient21 both used them — virtual-care platforms will increasingly be judged on unit economics capable of carrying debt, shifting diligence from user growth toward cost-per-episode-of-care.
The trend: Virtual healthcare funding is consolidating around end-to-end patient-journey platforms financed with blended equity and debt, squeezing out single-point tools.